Coya Therapeutics sets up $30,000,000 ATM program
Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC that allows the company to sell shares of its common stock from time to time in "at the market" offerings for aggregate gross proceeds of up to $30,000,000.
Rhea-AI Filing Summary
Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC that allows the company to sell shares of its common stock from time to time in "at the market" offerings for aggregate gross proceeds of up to $30,000,000.
The shares will be issued under an effective Form S-3 shelf registration statement and a prospectus supplement dated May 12, 2026. Leerink Partners will act as sales agent or, if separately agreed, as principal, and will receive a 3.0% commission on gross proceeds from any shares it sells.
Coya may suspend or terminate the program at any time, and the Sales Agreement will also end once all authorized shares are sold or if either party terminates it under the agreement’s terms.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM capacity: $30,000,000
Sales agent commission: 3.0% of gross proceeds
Shelf registration form: Form S-3, File No. 333-289511
+1 more
4 metrics
ATM capacity
$30,000,000
Maximum aggregate gross proceeds for Placement Shares
Sales agent commission
3.0% of gross proceeds
Commission payable to Leerink Partners on shares sold
Shelf registration form
Form S-3, File No. 333-289511
Registration statement used for Placement Shares
Prospectus supplement date
May 12, 2026
Date of prospectus supplement governing ATM sales
Key Terms
Sales Agreement, at the market, shelf registration statement, prospectus supplement, +2 more
6 terms
Sales Agreement financial
"entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC"
A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.
at the market financial
"sales deemed to be “at the market” equity offerings as defined in Rule 415"
“At the market” describes a method companies use to sell newly issued shares directly into the open market at whatever the current trading price is, usually through a broker who places shares in small amounts over time. Investors care because it can reduce each existing shareholder’s ownership percentage and increase the number of shares outstanding, while giving the company a flexible, quick way to raise cash — like adding single seats to a train instead of buying a whole new carriage.
shelf registration statement regulatory
"pursuant to a shelf registration statement on Form S-3 (File No. 333-289511)"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"as supplemented by a prospectus supplement dated May 12, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Rule 415 regulatory
"equity offerings as defined in Rule 415 promulgated under the Securities Act"
Rule 415 is a U.S. Securities and Exchange Commission regulation that lets a company register securities ahead of time and then offer them for sale in pieces over an extended period under a “shelf” registration, so offerings can be launched quickly when market conditions suit the issuer. For investors, it signals that management has a ready way to raise capital fast—useful for seizing opportunities but potentially dilutive to existing shareholders, like a company pre-loading a credit line it can tap as needed.
indemnification and contribution financial
"to provide Leerink Partners with customary indemnification and contribution rights"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Coya Therapeutics (COYA) announce in this 8-K filing?
Coya Therapeutics entered into a Sales Agreement with Leerink Partners LLC. The agreement allows Coya to sell common stock in at-the-market offerings for up to $30,000,000 in gross proceeds under an existing Form S-3 shelf registration statement.
How much stock can Coya Therapeutics (COYA) sell under the new Sales Agreement?
The Sales Agreement permits Coya Therapeutics to sell common stock for aggregate gross proceeds of up to $30,000,000. These shares, called Placement Shares, will be issued pursuant to a Form S-3 shelf registration and a May 12, 2026 prospectus supplement.
Who is acting as sales agent in Coya Therapeutics’ (COYA) at-the-market program?
Leerink Partners LLC will act as sales agent for Coya Therapeutics. Leerink Partners will use commercially reasonable efforts to sell Placement Shares in at-the-market offerings, primarily through the Nasdaq Capital Market, and may also buy shares as principal if separately agreed.
What commission will Leerink Partners earn under the Coya Therapeutics (COYA) Sales Agreement?
Leerink Partners will receive a commission of 3.0% of the aggregate gross proceeds from any Placement Shares it sells. Coya also agreed to reimburse certain expenses and provide customary indemnification and contribution rights under the Securities Act of 1933.
When does Coya Therapeutics’ (COYA) Sales Agreement with Leerink Partners terminate?
The Sales Agreement will end when all authorized Placement Shares have been issued and sold, or earlier if Coya or Leerink Partners terminates it under the agreement’s terms. Coya may also suspend offers under the program at any time at its discretion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
